BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rodríguez-Lago I, Hoyo JD, Pérez-Girbés A, Garrido-Marín A, Casanova MJ, Chaparro M, Fernández-Clotet A, Castro-Poceiro J, García MJ, Sánchez S, Ferreiro-Iglesias R, Bastón I, Piqueras M, Careda LEIB, Mena R, Suárez C, Cordón JP, López-García A, Márquez L, Arroyo M, Alfambra E, Sierra M, Cano N, Delgado-Guillena P, Morales-Alvarado V, Aparicio JC, Guerra I, Aulló C, Merino O, Arranz L, Hidalgo MA, Llaó J, Plaza R, Molina G, Torres P, Pérez-Galindo P, Romero MG, Herrera-deGuise C, Armesto E, Mesonero F, Frago-Larramona S, Benítez JM, Calvo M, Martín MDCL, Elorza A, Larena A, Peña E, Rodríguez-Grau MDC, Miguel-Criado J, Botella B, Olmos JA, López L, Aguirre U, Gisbert JP; Young GETECCU Group. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease. United European Gastroenterol J 2020;8:1056-66. [PMID: 32723069 DOI: 10.1177/2050640620947579] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Lin XX, Qiu Y, Zhuang XJ, Liu F, Wu XM, Chen MH, Mao R. Intestinal stricture in Crohn's disease: A 2020 update. J Dig Dis 2021;22:390-8. [PMID: 34014617 DOI: 10.1111/1751-2980.13022] [Reference Citation Analysis]
2 Chen BX, Han ZM, Zhou Q, Liu HB, Xu PC, Zhi FC. Efficacy of infliximab in treatment-naïve patients with stricturing small bowel Crohn's disease. Scand J Gastroenterol 2021;56:812-9. [PMID: 33962533 DOI: 10.1080/00365521.2021.1922748] [Reference Citation Analysis]
3 Loras C, Andújar X, Gornals JB, Sanchiz V, Brullet E, Sicilia B, Martín-arranz MD, Naranjo A, Barrio J, Dueñas C, Foruny JR, Busquets D, Monfort D, Pineda JR, González-huix F, Pérez-roldán F, Pons V, González B, Reyes Moreno J, Sainz E, Guardiola J, Bosca-watts MM, Fernández-bañares F, Mayor V, Esteve M. Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00386-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
4 Blesl A, Binder L, Högenauer C, Wenzl H, Borenich A, Pregartner G, Berghold A, Mestel S, Kump P, Baumann-Durchschein F, Petritsch W. Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study. Aliment Pharmacol Ther 2021;54:667-77. [PMID: 34151449 DOI: 10.1111/apt.16478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
5 Fousekis FS, Mitselos IV, Tepelenis K, Pappas-gogos G, Katsanos KH, Lianos GD, Frattini F, Vlachos K, Christodoulou DK. Medical, Endoscopic and Surgical Management of Stricturing Crohn’s Disease: Current Clinical Practice. JCM 2022;11:2366. [DOI: 10.3390/jcm11092366] [Reference Citation Analysis]
6 Archibugi L. UEGWeek: The modern School of Athens. United European Gastroenterol J 2021;9:877-82. [PMID: 35099123 DOI: 10.1002/ueg2.12149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sleiman J, El Ouali S, Qazi T, Cohen B, Steele SR, Baker ME, Rieder F. Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges. Expert Rev Gastroenterol Hepatol 2021;15:401-11. [PMID: 33225766 DOI: 10.1080/17474124.2021.1854732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Ando K, Uehara K, Sugiyama Y, Kobayashi Y, Murakami Y, Sato H, Kunogi T, Sasaki T, Takahashi K, Ueno N, Kashima S, Moriichi K, Tanabe H, Okumura T, Fujiya M. Correlation Among Body Composition Parameters and Long-Term Outcomes in Crohn's Disease After Anti-TNF Therapy. Front Nutr 2022;9:765209. [DOI: 10.3389/fnut.2022.765209] [Reference Citation Analysis]
9 Abdulla M, Chew TS. Molecular targets and the use of biologics in the management of small bowel fibrosis in inflammatory bowel disease. Curr Opin Gastroenterol 2021;37:275-83. [PMID: 33769380 DOI: 10.1097/MOG.0000000000000729] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Pagnini C, Cominelli F. Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention. Int J Mol Sci 2021;22:10273. [PMID: 34638616 DOI: 10.3390/ijms221910273] [Reference Citation Analysis]
11 Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology 2021;161:47-65. [PMID: 33940007 DOI: 10.1053/j.gastro.2021.04.063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Loras C, Mañosa M, Andújar X, Sánchiz V, Martí-Gallostra M, Zabana Y, Gutiérrez A, Barreiro-de Acosta M; en representación de GETECCU. Position Statement. Recommendations of the Spanish Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of strictures in Crohn's disease. Gastroenterol Hepatol 2021:S0210-5705(21)00219-3. [PMID: 34274357 DOI: 10.1016/j.gastrohep.2021.07.001] [Reference Citation Analysis]